RPG Life Sciences AGM clears ₹24 FY26 dividend

AGM outcome: dividend and board changes approved

RPG Life Sciences shareholders approved a final dividend of ₹24 per equity share for the financial year ended March 31, 2026, at the company’s 19th Annual General Meeting held on July 23, 2026. The meeting was conducted through video conferencing or other audio-visual means (VC/OAVM) and commenced at 3.00 p.m. IST. It concluded at 3:38 p.m., following the closure of the e-voting window.

Alongside the dividend, shareholders voted on board-related appointments and other statutory items. All six resolutions were passed with the requisite majority. The voting results were scrutinised by Parikh Parekh & Associates.

₹24 final dividend translates to 300% on ₹8 face value

The ₹24 per share final dividend corresponds to a 300% dividend on equity shares with a face value of ₹8 each. The dividend had been recommended by the Board at its meeting on April 29, 2026, and was subject to shareholder approval at the AGM, which has now been received.

The company had fixed July 9, 2026, as the record date to determine shareholder eligibility for the FY26 final dividend. It also communicated that the dividend would be paid within 30 days of the AGM to members whose names appear in the Register of Members or the depositories’ records on the record date.

Voting: near-unanimous support across resolutions

The ordinary resolution for the dividend received 100% support from votes polled, with only six votes cast against it out of more than 13 million total votes. Other key resolutions also saw near-unanimous approval.

The cut-off date for voting eligibility was July 16, 2026. The company disclosed that 24,393 shareholders were on record for the process.

Directors reappointed: Harsh V. Goenka and Manoj Maheshwari

Shareholders reappointed Harsh V. Goenka and Manoj Maheshwari as directors. Both were reappointed as Non-Executive Non-Independent Directors upon retirement by rotation under Section 152(6) of the Companies Act, 2013.

Each reappointment resolution received 99.33% votes in favour and 0.67% votes against. The company also disclosed that approximately 87,754 votes were cast against each appointment out of 13.1 million votes polled, indicating limited dissent.

Independent director appointment: Dr. Pratit Samdani

Dr. Pratit Samdani was appointed as an Independent Director for a five-year term commencing April 29, 2026, and ending April 28, 2031. The appointment required a special resolution and was approved with 99.99% votes in favour and 0.00% votes against, as per the disclosed table.

Cost auditor remuneration ratified for FY27

Shareholders ratified the remuneration payable to Kirit Mehta & Co., the company’s cost auditors, for the financial year ending March 31, 2027. This ordinary resolution was approved with 100% of the votes polled in favour.

Snapshot table: resolutions and voting results

Key dates: record date, voting cut-off, and tax documentation

Ahead of the dividend decision, RPG Life Sciences fixed July 9, 2026 as the record date for the final dividend. The cut-off date for voting eligibility was July 16, 2026. Separately, the company set July 3, 2026 as the deadline for shareholders to submit documentation for tax exemptions on the FY26 final dividend.

For non-resident shareholders, the company flagged a withholding tax rate of 20%, plus surcharge and cess, unless benefits under the Double Taxation Avoidance Agreement (DTAA) are opted for. Documentation was to be submitted to MUFG Intime India Private Limited via post or registered email by the stated deadline.

Market context: stock price move cited in disclosures

The provided data also referenced a price move where the share price moved down by -4.28% from its previous close of ₹2,414.20, and the last traded price was cited as ₹2,311.10. The same dataset also stated: “RPG Life Sci share price is ₹2,311.10 as on 12 May, 2026, 03:44 PM IST.” These price points were presented alongside the dividend information and corporate action references.

Business update mentioned: Naprosyn ES tie-up

In addition to corporate actions, the information noted that RPG Life Sciences has partnered with Archerchem Healthcare to exclusively market and distribute Naprosyn ES in India. The product was described as a combination of Naproxen and Esomeprazole designed for long-term pain management with gastro-protection.

Why the AGM vote matters for shareholders

The AGM outcome formalises the FY26 capital return via the ₹24 per share final dividend and confirms the company’s board composition through reappointments and a new independent director appointment. The voting distribution, including 100% support recorded for multiple ordinary resolutions and near-unanimous support for director-related items, indicates broad alignment among participating shareholders on the proposals placed.

Next, the key operational step on the dividend side is the payment process within 30 days of the July 23, 2026 AGM, for eligible shareholders as determined by the July 9, 2026 record date.